BACKGROUND: Aggressive surgical resection with intent to cure and surgical debulking procedures are commonly recommended in patients with metastatic pheochromocytoma and paraganglioma. To date there are no data on operative outcomes of patients after surgical resection of metastatic pheochromocytoma and paraganglioma to determine if such an approach is appropriate and what factors may be associated with a favorable outcome. STUDY DESIGN: We performed a retrospective analysis of 30 patients with metastatic pheochromocytoma/ paraganglioma who underwent surgical treatment. Clinical characteristics and genetic factors were analyzed as predictors of biochemical response to surgery.
catecholamines, with the notable exception of head and neck paragangliomas, which are often biochemically inactive. 2, 3 Malignant pheochromocytoma/paraganglioma is defined by the presence of tumor at sites normally devoid of chromaffin cells or by local invasion by the primary tumor. [4] [5] [6] The rate of metastatic disease is variable, with reports ranging from 2.5% to 40%. [6] [7] [8] Recurrence, either locoregional or metastatic, usually occurs within 5 years of initial complete resection but has been reported up to 40 years postoperatively. 8 Multiple nonanatomic parameters have also been associated with metastatic disease. Pathologic features more often associated with metastatic disease include primary tumor size greater than 6 cm, necrosis, hemorrhage, and high mitotic index. 9, 10 Possible biochemical indicators of malignant disease include dopamine hypersecretion measured by methoxytyramine, or markedly elevated plasma or urinary metanephrines. [10] [11] [12] [13] The most well defined genetic risk factor for malignant disease is a mutation in the SDHB gene, which is clinically associated with an earlier onset of disease and more aggressive malignancy. 2, 14, 15 Surgical resection is the only potentially curative treatment for pheochromocytomas and paragangliomas. 16 Initial complete resection with intent to cure (R0) has been shown to improve survival, while surgical debulking is often used in an attempt to achieve biochemical control, improve response to systemic therapies, palliate symptoms, or simply to decrease tumor burden. 5, 6, 17, 18 However, there are no data on the benefits of aggressive resection or debulking in the setting of locally invasive, metastatic, or recurrent disease. [18] [19] [20] Furthermore, there are currently no clinical, genetic, or pathologic parameters that clinicians can rely on to guide operative decision making. This study sought to characterize outcomes of patients who underwent operation for locally invasive, metastatic, or recurrent pheochromocytoma/paraganglioma and identify clinical factors that might aid in patient selection and determine patient outcomes.
METHODS

Patients
Data pertaining to patient demographics, genetic tests, pathology, radiology, and operative history were reviewed in patients with malignant and metastatic pheochromocytomas and abdominal paragangliomas, who were evaluated at the National Institutes of Health (NIH) Warren Magnuson Clinical Center on clinical protocols. All patients underwent genetic testing for mutations and deletions in SDHA, SDHB, SDHC, SDHD, SDHAF2, RET, VHL, and TMEM127. These genetic tests were performed in collaboration with the Mayo Clinic in Rochester, MN. Postoperative follow-up consisted of biochemical testing (plasma catecholamines, metanephrines) and imaging studies (CT, MRI, and FDG-PET imaging) as part of the NIH clinical protocol. Postoperative follow-up consisted of biochemical testing (plasma catecholamines, metanephrines) and interval imaging studies (CT, MRI, and FDG-PET imaging) as part of the NIH clinical protocol. This review led to identification of 61 patients who underwent an operation for biochemically active malignant disease. Of those, 30 patients receiving a total of 42 operations had adequate preoperative data and postoperative follow-up to be included in this study.
Classification of laboratory values
Biochemical laboratory values were used as the primary indicator of disease burden, remission, and recurrence. Any biochemical elevation above the upper limit of normal was considered evidence of disease. Seven laboratory values were used as disease surrogates: chromogranin A (upper limit of normal, 225 ng/mL); plasma fractionated metanephrines (61 pg/mL), normetanephrines (112 pg/mL), epinephrine (83 pg/mL), norepinephrine (498 pg/mL), and dopamine (46 pg/mL); and 24-hour urinary fractionated metanephrine and normetanephrine (400 mg/24hours). Patients were instructed to discontinue use of medications that may result in false positive results before laboratory testing, with blood pressure monitoring when off medications. Laboratory studies performed within 3 months of the intervention were used as surrogates for preoperative disease burden. Postoperative values were categorized into 3-and 6-month intervals and were recorded for the duration of follow-up (median 24 months, range 1 to 99 months). Only patients with preoperative laboratory values and postoperative laboratory samples drawn within 6 months of the intervention were included in the study cohort using the same assay, and only those laboratory tests with known preoperative and postoperative values were considered for analysis.
Classification of disease at presentation Currently, there is no widely accepted staging system for malignant pheochromocytoma/paraganglioma. For the purposes of this study, the extent of disease was classified based on preoperative anatomic imaging results. Patients were separated into 4 major subgroups based on anatomic tumor burden: locoregional disease, abdominal metastasis, thoracic metastasis, and bony metastasis. Locoregional disease was considered only in the setting of gross local invasion of surrounding organs or soft tissues. Using these data, patients were further grouped into 2 categories. Category 1 consisted of patients with tumor confined to the abdomen, either locoregional or metastatic. Category 2 consisted of patients with metastatic disease outside the abdomen.
Statistical analysis
The primary outcome variables analyzed were durations of biochemical response. Disease-free interval was defined by complete biochemical remission, with all indicative laboratory values returning to the normal range postoperatively. Partial biochemical response was defined as having at least 1, but not all, biochemical laboratory values returning to the normal range postoperatively.
Initial data analysis was performed including all 42 operations. To assess whether there was appreciable bias from the use of multiple operations, analysis was validated using only the initial operation for each of the 30 patients. The association between clinical and genetic factors and length of biochemical response was assessed using Kaplan-Meier survival analysis. The statistical difference between Kaplan-Meier curves was determined using the log-rank test. The Cox proportional hazards model was used to determine the joint significance of factors associated with return of laboratory values to normal levels. The associations between the outcomes parameters and clinical variables were determined by Fisher's exact test when comparing a dichotomous parameter, Mehta's modification to Fisher's exact test when comparing to categorical values, and an exact Cochran-Armitage test when comparing categorical results. 21 All p values are 2-tailed and presented without any adjustment for multiple comparisons; so, p < 0.005 was used as a cut-off for statistical significance due to the number of tests performed.
RESULTS
Patient characteristics
Of the 30 patients in the study cohort, 7 patients underwent multiple operations. Only 2 of the 7 patients with multiple operations included had more than 2 procedures: 1 patient had 6 operations over 6 years, and another patient had 3 operations in 3 years. Twelve (40%) patients had a germline mutation in the SDHB gene, with 1 patient positive for SDHD. The other 17 (56.7%) patients had sporadic tumors not associated with any known genetic abnormality. Additional clinical characteristics of the study cohort are summarized in Table 1 .
Biochemistry
The mean number of elevated preoperative laboratory values was 3.0 AE 1.8 (range 1 to 7). The absolute number of elevated preoperative laboratory values was not predictive of biochemical response to surgery (p ¼ 0.89).
Preoperative laboratory value elevations are summarized in detail in Table 2 .
Extent of disease Twenty-four of the primary tumors were adrenal pheochromocytomas; 6 were abdominal extra-adrenal paragangliomas (Table 1) . Of the 42 operations analyzed, 27 were performed on patients with Category 1 disease (12 locally advanced, 15 abdominal metastasis) and 15 Among the demographic, genetic, and clinical factors analyzed, only preoperative extent of disease was significantly associated with duration of biochemical response to surgery. Patients with Category 1 disease (confined to the abdomen, either locoregional or metastatic) were significantly more likely to achieve biochemical response than patients with Category 2 (extra-abdominal) disease (74.1% vs 20.0%, p ¼ 0.0009). This response was also substantially more durable in Category 1 patients, with more than 40% maintaining a response 3 years postoperatively (p ¼ 0.0003, Fig. 1 ). Patients with SDHB mutations appeared to demonstrate a less durable biochemical response, but this result did not achieve statistical significance (p ¼ 0.021, Fig. 2 ). The presence of the classic symptom triad (headache, palpitations, and diaphoresis) was also associated with a shorter duration of biochemical response, but did not reach statistical significance (p ¼ 0.0145). Fourteen patients received some form of systemic therapy, with 12 receiving cyclophosphamide, vincristine, and dacarbazine (CVD) chemotherapy, 4 receiving high dose I-131 metaiodobenzylguanidine therapy, and 7 receiving external beam radiation. Systemic therapy was not significantly associated with postoperative biochemical response (Table 3) .
Although these clinical factors were associated with clinical response, presence of residual disease postoperatively Fig. 3 ). Patients were also less likely to obtain pharmacologic independence after debulking (p ¼ 0.0003), with only 2 (8.3%) not requiring alpha-blockade 6 months after the intervention (Fig. 4) . The magnitude of biochemical response for selected subgroups is presented in Figure 5 .
DISCUSSION
Our study examined the results of 42 operations for metastatic pheochromocytoma/paraganglioma and analyzed factors associated with overall survival, disease-free survival, and biochemical response to surgery. Patients who presented with disease confined to the abdomen (Category 1) were significantly more likely to achieve and maintain a biochemical response, and may be more Vol
likely to achieve biochemical remission from surgical resection. Unfortunately, the majority of patients have biochemical recurrence within 1 year and less than 30% maintain biochemical response 5 years after surgery. We also found poor biochemical outcomes from debulking procedures, with less than 5% of debulking procedures leading to even partial normalization of laboratory values 12 months postoperatively (Fig. 3) . The analysis also showed a statistical trends toward worse operative outcomes in patients with SDHB mutations (Fig. 2) and in patients whose initial presentation involved the classic symptom triad of headache, palpitations, and diaphoresis. The very low overall mortality (4 of 30, 13.3%) and low frequency of complete disease remission (10 of 42, 23.8%) in our cohort precluded a meaningful KaplanMeier analysis of overall survival and disease-free survival, respectively, given the relatively small sample size. Of these results, the ineffectiveness of surgical debulking procedures is most striking. Although the finding that debulking is oncologically inferior to complete resection is intuitive, the low rates of biochemical response after such procedures should be helpful data when considering a patient for such an operation. This is because debulking procedures are often considered mainstays in operative management of patients with hyperfunctioning malignant disease, partially due to the presumed decrease in overall catecholamine secretion leading to symptomatic control and improved cardiovascular outcomes. 12, 17, [22] [23] [24] [25] [26] It is also often presumed that extraperitoneal disease is dedifferentiated and less likely to contribute to overall catecholamine secretion, which may lead some to consider aggressive abdominal debulking operations. However, in our cohort, patients with extra-abdominal metastases with gross resection of abdominal disease did not achieve desirable biochemical outcomes.
Our study identified extra-abdominal disease as an indicator of poor surgical outcomes, and challenges the broad utility of debulking procedures as an effective way to ameliorate biochemical activity of pheochromocytomas and paragangliomas. We believe these findings contribute to medical decision making and operative planning for these patients. Our data indicate that aggressive debulkings should not be used purely to decrease biochemical burden unless there is a reasonable chance of complete resection. This is especially true when noting the general effectiveness of pharmacologic therapy in symptom control, as well as the unclear link between catecholamine secretion and cardiovascular outcomes. 19, [26] [27] [28] [29] A more aggressive approach to abdominal debulking may be warranted, even in cases in which complete resection is unlikely, if disease has not spread beyond the abdominal cavity. It is important to note, however, that palliative operations indicated for symptoms such as pain or shortness of breath should not be withheld due to these data. Safe, low morbidity operations may alleviate patient discomfort regardless of biochemical response and may be warranted based on clinical judgment.
There are several limitations to our study. This is a retrospective analysis and does not have a control cohort managed without surgical intervention, which limits the strength of our conclusions. Clinical assessment of surgical outcomes would be significantly strengthened by evaluation of a cohort of patients with malignant pheochromocytoma/paraganglioma managed nonoperatively, but this is unlikely to exist given the rarity of the disease and the lack of effective treatment alternatives. Our clinical database did not contain any standardized symptom or quality of life review forms, which hinders quality of life assessment of subjective patient variables such as pain. The use of biochemical laboratory values as surrogates for disease burden also has pitfalls. Catecholamine secretion by pheochromocytomas and paragangliomas is cyclical, so laboratory markers of disease may not be accurate. 30 However, catecholamines such as urinary metanephrines have been shown to be good surrogates for tumor burden. 22 False-positive biochemical testing results may occur when the elevation in catecholamine and metabolites is less than 2 times the upper limit of normal during the initial work up of patients to exclude pheochromocytoma/paraganglioma. However, all the patients in this study had malignant disease with biochemical elevation of catecholamine and metabolites, and axial imaging demonstrating the disease before reoperation. Furthermore, only 1 patient in the study cohort had laboratory elevations below twice the upper limit of normal during follow-up. Finally, aggressive debulking of tumor may be clinically warranted as low morbidity, minimally invasive procedures such as radiofrequency ablation are further evaluated, especially in patients with liver metastasis. 31 
CONCLUSIONS
In summary, our results indicate that patients without extra-abdominal disease are more likely to achieve both remission and a durable biochemical response from aggressive resection of metastatic pheochromocytoma or paraganglioma, and debulking operations are unlikely to lead to sustained control of catecholamine secretion or pharmacologic independence. Based on our results, we believe that debulking procedures in patients with extraabdominal metastases should be based only on palliating patient symptoms and not on a preoperative goal of biochemical remission. Conversely, a more aggressive operative approach should be offered to patients with exclusively intra-abdominal disease with a goal of postoperative biochemical remission when a complete resection (RO/R1) is possible.
